BioSpace News Archive

The Mark Foundation for Cancer Research has awarded six new Emerging Leader Awards, totaling $4.5 million, to outstanding early-career investigators for projects aimed at addressing unmet needs in cancer research.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma Bright” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has signed a SPA (Share Purchase Agreement) with Inretio Ltd.

Outlook Therapeutics, Inc. announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence.

Araris Biotech AG announced that Bernd Schlereth, Ph.D., chief development officer, will deliver an oral presentation at the 22nd annual PepTalk: Protein Science and Production Week being held January 16- 20, 2023 in San Diego.

Aprea Therapeutics, Inc. announced that it will participate in the 6th Annual DDR Inhibitors Summit, held in Boston, Massachusetts from January 24 – January 26, 2023.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug Application (NDA) for obeticholic acid (OCA) seeking accelerated approval for the treatment of patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH).

Eurofins CellTx, an industry leader in regulated testing services for living donor eligibility testing, announced the official opening of its new laboratory in Tucson, AZ.

German medical device manufacturer PARI and smartShift, leading global provider of Intelligent Automation for SAP transformations based in Mannheim/Germany, announce their collaboration on the planned S/4HANA transformation for PARI group’s validated SAP systems.

Cardurion Pharmaceuticals Strengthens Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (PK) profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers.